Comparing imaging techniques for predicting desmoid tumor progression after cryoablation
Official title: Confronto Tra Radiomica e i Criteri Convenzionali di Risposta Nella Previsione Della Progressione Del Tumore Desmoide Dopo Crioablazione
Run by Istituto Ortopedico Rizzoli · NCT06224283 · Data updated 2026-11-12
This study is testing if a new imaging method can better predict how desmoid tumors change after cryoablation treatment compared to standard methods.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 21 (estimated) |
| Sponsor | Istituto Ortopedico Rizzoli Academic / other |
| Locations | 1 site (Bologna) |
| Status | Recruiting |
| Started | February 20, 2024 |
| Main results expected | October 31, 2026 |
| Study ends | October 31, 2026 |
| Registry record updated | May 12, 2026 |
| Trial ID | NCT06224283 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with desmoid tumors who have received cryoablation treatment and have undergone baseline MRI.
✕Probably not a fit
Patients who do not have desmoid tumors or have not undergone cryoablation will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the effectiveness of radiomics compared to conventional response criteria in predicting the progression of desmoid tumors following cryoablation treatment. Desmoid tumors, while benign, can be locally aggressive and cause significant discomfort. The study involves patients who have undergone cryoablation at the Rizzoli Orthopaedic Institute, with follow-up MRI assessments to monitor changes in tumor heterogeneity over time. The goal is to identify early indicators of tumor response that may not be captured by traditional size-based criteria.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management strategies for patients with desmoid tumors, enhancing treatment outcomes.
How similar studies have gone: Other studies have shown promise in using advanced imaging techniques for tumor assessment, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * desmoid tumor treated at Rizzoli Orthopaedic Institute with cryoablation * baseline MRI * clinical and radiologic follow-up until disease progression or the start of a new line of treatment performed every 3 months, with a minimum of 6 months follow-up Exclusion Criteria: \- not meeting inclusion criteria
Where it's running
-
Giancarlo Facchini
Bologna, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using chemoembolization to treat desmoid fibromatosis
This study is testing a new way to treat desmoid fibromatosis by using a targeted chemotherapy method for patients with growing tumors who can’t have surgery.
-
FOG-001 treatment for advanced or metastatic solid tumors
This study is testing a new drug called FOG-001 to see if it can help people with advanced solid tumors, especially those with certain genetic changes, when traditional treatments aren't working.
-
Using cryotherapy to treat desmoid tumors
This study is testing whether cryotherapy can be a safe and effective treatment for adults with desmoid tumors, offering a new option for those who may not want chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.